Name That Brand: May 2012

Can you name the brand? Each month we print part of a popular pharmaceutical product or advertisement, with clues to its identity. Readers are invited to name the brand for a chance to win a copy of Medicine Ave 2: The Story of Medical Advertising in America 1990-2008. E-mail your answer to NameThatBrand@haymarketmedia.com or fax 646-638-6150. The deadline is May 31, 2012. The winner will be picked randomly from the correct entries.

 

Brand X lights up its message
Among 2010's most detailed products, May's drug also topped the list of most-likely-to-be-prescribed following a sales visit. The advertising for this physician favorite is a bit of a mixed metaphor, with two colors swirling upwards, while the two-part compound is in fact all about decline. And the brand's sales reps may have been working at cross purposes as well, with accusations that they offered off-label advice for the drug whose primary audience could include almost 68 million, or 1 in 3 adults.

MARCH'S WINNER...
No one was able to correctly identify March's Name That Brand. The answer was Merck's Victrelis, a prescription medicine indicated to treat chronic hepatitis C infections.
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.